NEWS & EVENTS

Catalent today announced that Mr. Michael Merges, Director of Strategic Growth, Catalent Biologics Analytical Services, will be presenting at the upcoming WCBP Conference in Washington DC, on Jan. 24 – 26, 2017.

Catalent today announced it has signed an agreement with PATH, an international nonprofit organization and a leader in global health innovation, to advance a project funded by its Malaria Vaccine Initiative (MVI).

Catalent Pharma Solutions celebrated its ground breaking for a new $34 million extension to its state-of-the-art Madison, Wisconsin biologics manufacturing facility on Friday, Oct. 21.

Catalent announced today that it has partnered with Moderna Therapeutics to support near-term clinical GMP mRNA manufacturing efforts for Phase 1/2 clinical studies of the company’s mRNA personalized cancer vaccines.

Catalent Pharma Solutions today announced that its OptiForm® Solution Suite and OptiForm® Solution Suite Bio platforms have won the ‘Excellence in Pharma: Contract Services and Outsourcing’ award at the annual CPhI Pharma Awards.

Catalent and Triphase Accelerator Corporation today announced that Triphase will obtain worldwide rights to further develop Catalent’s proprietary CD22-4AP Antibody-Drug Conjugate (ADC), which has been developed by Catalent’s subsidiary, Redwood Bioscience, Inc.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the appointment of Dr. William E Haskins as Director of R&D, Bioanalytical Chemistry.

Catalent Pharma Solutions and Zumutor Biologics Inc. today announced a successful research study, combining Catalent’s proprietary GPEx® technology and Zumutor’s fucose knockout platform, to create new and more efficacious antibodies.

Catalent Pharma Solutions today announced that it is extending its OptiForm® Solution Suite technology platform to introduce rapid screening of macromolecules’ suitability for non-invasive drug delivery.